Dynavax Reports Positive Test Results

Trial results for Dynavax Technologies Corp.'s (DVAX) experimental hepatitis B vaccine showed 100% protection compared with a competitor's 73% effectiveness rate. The stock price leaped $2.39 to close at $9.79.